Viewing StudyNCT01752920

Bugs

eRecord

Ignite Creation Date: 2024-05-06 @ 1:12 AM

Last Modification Date: 2024-10-26 @ 11:00 AM

Study NCT ID: NCT01752920

Status: COMPLETED

Last Update Posted: 2023-06-05

First Post: 2012-12-14

Brief Title: Phase 12 Study of Derazantinib ARQ 087 in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations

Sponsor: Basilea Pharmaceutica

Organization: Basilea Pharmaceutica

Overview Dates Organization Conditions Design Enrollment Locations Outcomes

Conditions:

Name

Solid Tumor

Keywords:

Name	View

FGFR	View
ARQ 087	View
Targeted therapy	View
Molecular therapy	View
Tyrosine kinase inhibitor	View
TKI	View
Receptor tyrosine kinase	View
RTK	View
Biomarker	View
Phase 1	View
Phase I	View
Solid tumor	View
Liver Cancer	View
Hepatobiliary carcinoma	View
Biliary tract cancer	View
Cholangiocarcinoma	View
Intrahepatic cholangiocarcinoma	View
FGFR inhibitor	View
Targeted FGFR kinase inhibitor	View
Pan-FGFR inhibitor	View
Selective FGFR inhibitor	View
FGFR pathway	View
FGFR signaling	View
Fibroblast growth factor	View
FGFR1	View
FGFR2	View
FGFR3	View
FGFR4	View
FGF	View
FGF19	View
FGF21	View
FGF23	View
FGFR mutation	View
FGFR gene fusion	View
FGFR gene translocation	View
FGFR genetic aberration	View
FGFR2 fusion	View
FGFR2 translocation	View
Phase 1 Clinical Trial	View
Phase I Clinical Trial	View
Clinical oncology	View
Tumor	View
Tumour	View
derazantinib	View
MK-2921	View